Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding column provides a comprehensive monthly review of emerging life science companies that have received VC funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced June through August 2014.

Antabio SAS is taking an antivirulence rather than an antibiotic approach to treat gram-negative nosocomial infections. When combined with marketed antibiotics, the compounds in its pipeline have potential to target key virulence pathways in pathogenic bacteria, and thus reduce patient mortality and associated costs.

A preview of the emerging health care companies profiled in the current issue of Start-Up. "As Drug-Resistant Microbes Rise, Antibiotic Start-Ups Need Savvy Investors," features profiles of Cempra Pharmaceuticals, DesignMedix, Kenta Biotech and MGB Biopharmaceuticals. Plus these Start-Ups Across Health Care: CardioPhotonics, Eureka Genomics, Invuity and OrthoSensor.

VCs see rich exit opportunities, especially for start-ups with multiple products in their pipelines. In this issue we profile four emerging antibiotic drug developers: Cempra Pharmaceuticals, DesignMedix, Kenta Biotech and MGB Biopharma.